Vaccine Insights

Optimized and scalable #LNP composition for #RNAvaccinedelivery #Lipidnanoparticle (LNP)-encapsulated #RNAvaccines have been crucial in combating #COVID-19 and are now gaining momentum against other infectious diseases. However, challenges such as limited access to potent #ionizablelipids and the need for significant expertise in formulation and scale-up remain. Next month, Cytiva’s Martin Rabel (Services Solution Specialist) will introduce a novel ionizable lipid developed for the delivery of RNA in #vaccine applications, accelerating payload screening and #LNPoptimization. Register for this #webinar below:

Impact of #glycosylation of #vaccineantigens on quality and performance Glycosylation of proteins used as #vaccine antigens can impact the safety and efficacy of the vaccine and thus can be a product quality attribute. The composition and position of glycans within the protein structure can also affect function, as well as trafficking to cellular sub-compartments and specific tissues. Read this expert insight with John Cipollo (Senior Principal Scientist and Team Lead, US Pharmacopeia) and Diane McCarthy (Senior Scientific Director, Global Biologics, US Pharmacopeia) to learn more about vaccine antigen glycosylation, including its biological relevance, examples where monitoring could improve #vaccineperformance, relevant analytical approaches, and existing resources and guidance for industry on the analysis of glycosylation Access below:

#FastFacts now available! Accelerate #vaccine development with novel #affinitypurification solutions As the landscape of #vaccineproduction continues to expand, it becomes crucial to develop highly efficient purification solutions that can address the growing diversification of vaccine modalities. This FastFacts explores the advantages of #affinitychromatography in streamlining the #vaccinepurification bioprocesses Access below:

#Viewpoint now available! How can investing in technology transfers help build a sustainable manufacturing ecosystem? An example from #cholera Read this viewpoint with Charlotte Weller (Head of Prevention, Infectious Disease, Wellcome) and Jeanette Hayes (Research Manager, #Vaccines, Wellcome) for insight into the #cholerapandemic and what action is being taken on it. Access below:

#RSVvaccines: a new hope but the virus might strike back There are three RSV #vaccines at once—two for use in the elderly (Arexvy and Abrysvo™) and one as a maternal vaccine (Abrysvo). In parallel, there is a new #monoclonalantibody, nirsevimab. Both the vaccines and the antibody target the RSV-F protein. In this #review, we will give an overview of the #antibodies and the vaccines and look at the #immunological, viral, economic, and societal challenges that might arise in the next few years to avoid the return of the virus. Read below:

The manufacturing of #COVID-19 vaccines demonstrated how #vaccineproduction can be rapidly scaled up with faster regulatory approval and time to market. Advances in purification technology and #analyticaltools in recent years has led to an increased market value and manufacturing capacity for vaccines; however, challenges remain. This #infographic offers a step-by-step overview of manufacturing and analytical methods for four key #vaccine types: #VLP (virus-like-particle), subunit, #mRNA, and #viralvectorvaccines View below:

#Vaccinesecurity and self-reliance in South East Asia #Vaccine security and self-reliance must be a priority for all nations if they are to escape the worst health and economic impacts of future pandemics. The newly launched UK-South East Asia #VaccineManufacturing Research Hub will support South East Asia to become a global leader in vaccine production by addressing key priorities including technology transfer, #IP, standardization, and supply chain. Read more about this below:

What’s next for #COVIDvaccines? While first-generation #COVID-19 vaccines were highly successful, waning #immunity and the rapid evolution of the virus mean that new approaches are needed. In this Viewpoint, Jeffrey B Ulmer (President, TechImmune LLC) and Lbachir BenMohamed (Professor of Immunology, Gavin Herbert Eye Institute, School of Medicine, UC Irvine, and Vice-President for Research, TechImmune LLC) describe several promising strategies with the potential to overcome the limitations of current #vaccines. Read more below:

Interview now available! Charting a course for better #pneumococcalvaccines In January this year, Vaccine Insights editor, Charlotte Barker spoke with Richard Malley (Senior Physician in Pediatrics, Boston Children’s Hospital, and Professor of Pediatrics, Harvard Medical School) about charting a course for better pneumococcal vaccines. A new platform for developing bacterial vaccines—the multiple antigen presenting system—could enable an affordable alternative to current pneumococcal conjugate vaccines. In this interview, the fast-evolving pneumococcal vaccine field is discussed. Read at your convenience below:

Don't miss out on the May Vaccine Insights issue! Featuring this month's spotlight content: RNA vaccines: research directions View below: